Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors
Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
